Bausch + Lomb Reports Strong Financial Growth

By Bobby Samwell • Wednesday, February 19 10:47 • Permanent Link

Bausch + Lomb, a leading global eye health company, has announced its fourth-quarter and full-year 2024 financial results, showcasing a solid performance and growth across all segments.

In the fourth quarter of 2024, Bausch + Lomb reported revenue of $1.280 billion, representing a 9% increase compared to the same period in 2023. Adjusted EBITDA, excluding acquired IPR&D, was $259 million for the quarter, reflecting a growth of 11% on a constant currency basis.

For the full year of 2024, the company reported revenue of $4.791 billion, marking a 16% increase compared to 2023. Adjusted EBITDA, excluding acquired IPR&D, stood at $878 million, showcasing a 17% growth on a constant currency basis.

Revenue growth was observed across all segments, with the Vision Care segment reporting revenue of $723 million in the fourth quarter of 2024, marking a 9% increase from the same period in 2023. The Surgical segment also saw significant growth, with revenue of $231 million, reflecting a 13% increase compared to the fourth quarter of 2023. The Pharmaceuticals segment reported revenue of $326 million, representing a 6% increase from the fourth quarter of 2023.

The company's operating income for the fourth quarter of 2024 was $87 million, a substantial increase from $49 million in the same period of 2023. However, the net loss attributable to Bausch + Lomb Corporation for the fourth quarter of 2024 was $3 million, a significant improvement from the net loss of $54 million in the fourth quarter of 2023.

For the full year of 2024, Bausch + Lomb's adjusted net income attributable to the corporation was $204 million, compared to $258 million in 2023. The company reported cash flow from operations of $232 million for the full year of 2024, representing a significant increase from the cash flow used in operations of $17 million in 2023.

Looking ahead, Bausch + Lomb provided guidance for the full year of 2025, projecting a revenue range of $4.950 billion to $5.050 billion, with approximately 5.5% to 7.5% constant currency growth. The company also anticipates adjusted EBITDA, excluding acquired IPR&D, to range between $900 million and $950 million for the full year of 2025. However, the company noted potential foreign exchange headwinds, projecting a negative impact of $100 million on full-year revenue and $20 million on adjusted EBITDA for the same period.

Following these announcements, the company's shares moved -0.8%, and are now trading at a price of $16.22. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.